A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2002
11/26/2002	US6486142 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
11/26/2002	US6486141 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
11/26/2002	US6486122 Methods of increasing body weight in a subject by administering TGF-α
11/26/2002	US6485760 Method for inhibiting increase of blood sugar level or lowering blood sugar level with a lagerstroemia extract
11/26/2002	US6485745 Dosage form exhibits accelerated release of the active agent
11/26/2002	US6485742 Process for producing coated preparation and its use
11/26/2002	US6485706 Dehydration product of insulin and an orally effective nonsteroidal membrane-permeation enhancer, for administration to buccal mucosa via spraying suspension of solid particles
11/26/2002	CA2355247C Method for the prevention and treatment of cachexia and anorexia
11/26/2002	CA2258285C Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
11/26/2002	CA2100864C Method for delivering direct feed microorganisms to poultry in ovo
11/26/2002	CA2098838C Liver enriched transcription factor
11/26/2002	CA2078555C Novel vitamin d analogues
11/25/2002	WO2001090087A1 Heterocyclic compounds
11/25/2002	CA2410382A1 Heterocyclic compounds
11/21/2002	WO2002092817A1 Functions for d52 and ra006 nucleic acids and polypeptides
11/21/2002	WO2002092808A1 Random gene unidirectional antisense library
11/21/2002	WO2002092807A1 Unigene unidirectional antisense library
11/21/2002	WO2002092781A2 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002	WO2002092773A2 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
11/21/2002	WO2002092772A2 Antisense modulation of ptp1b expression
11/21/2002	WO2002092764A2 Transgenic animal model of bone mass modulation
11/21/2002	WO2002092759A2 Molecules for disease detection and treatment
11/21/2002	WO2002092756A2 Insulin producing cells derived from human embryonic stem cells
11/21/2002	WO2002092630A1 High density lipoprotein-reactive peptides
11/21/2002	WO2002092597A1 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.0?2,11.04.9¿)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	WO2002092593A1 4-(4-pyridazinyl)pyrazole derivatives
11/21/2002	WO2002092590A1 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
11/21/2002	WO2002092585A1 Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
11/21/2002	WO2002092576A1 Diarylurea derivatives useful as anti-inflammatory agents
11/21/2002	WO2002092573A2 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
11/21/2002	WO2002092571A1 Novel 4-anilinoquinoline-3-carboxamides
11/21/2002	WO2002092566A1 Arginine derivatives
11/21/2002	WO2002092563A2 Protease inhibitors
11/21/2002	WO2002092558A1 Polythiourea lipid derivatives
11/21/2002	WO2002092553A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
11/21/2002	WO2002092540A1 Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsatruated fatty acids from microbes, genetically modified plant seeds and marine organisms
11/21/2002	WO2002092122A2 Use of osteopontin for the treatment and/or prevention of neurologic diseases
11/21/2002	WO2002092095A1 Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
11/21/2002	WO2002092093A1 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes
11/21/2002	WO2002092090A1 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
11/21/2002	WO2002092089A1 Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	WO2002092087A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
11/21/2002	WO2002092084A1 Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
11/21/2002	WO2002092067A1 Compositions for transmucosal administration containing coenzyme q as the active ingredient
11/21/2002	WO2002092064A2 Therapeutic method for inducing tolerance
11/21/2002	WO2002092058A1 Rapidly disintegratable solid preparation
11/21/2002	WO2002092015A2 Reagents and methods for modulating dkk-mediated interactions
11/21/2002	WO2002092004A2 Use of hmg fragment as anti-inflammatory agents
11/21/2002	WO2002092000A2 Hbm variants that modulate bone mass and lipid levels
11/21/2002	WO2002091993A2 Estrogen receptor modulators
11/21/2002	WO2002091988A2 Novel processes for the preparation of adenosine compounds and intermediates thereto
11/21/2002	WO2002080877A3 Use of alverine or one of its salts
11/21/2002	WO2002076381A3 Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
11/21/2002	WO2002070507A3 Glycorticoid receptor antagonists for treatment of diabetes
11/21/2002	WO2002067953A3 Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia
11/21/2002	WO2002063308A3 Prediction of wound healing by urinary nitrate assay
11/21/2002	WO2002058733A9 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
11/21/2002	WO2002058532A3 Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof
11/21/2002	WO2002055514A3 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators
11/21/2002	WO2002051264A3 Nutritional composition with health promoting action containing oligo-saccharides
11/21/2002	WO2002049649A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
11/21/2002	WO2002042271A3 Biphenylcarboxamides useful as lipid lowering agents
11/21/2002	WO2002000730A3 Pd-l2 molecules: novel pd-1 ligands and uses therefor
11/21/2002	WO2001019397A9 Methods and compositions utilizing rad51
11/21/2002	US20020173661 Phosphodiesterase-4 (PDE4); thiazole-containing pyridine (N-oxide) compounds; 4-(2-(3,4-Bis(difluoromethoxy)phenyl)-2-(5-(2-(1-hydroxy-1 -methyl)ethyl)thiazolyl)ethyl)pyridine N-oxide for example
11/21/2002	US20020173647 Polymorphic/pseudopolymorphic forms of arginine salt of 3-(4-(2-(phenoxazin-10-yl)ethoxy)phenyl)-2-ethoxypropanoic acid
11/21/2002	US20020173646 Quinazoline derivatives and pharmaceutical compositions containing them
11/21/2002	US20020173642 Human gastric cancer antigen gene and gastric cancer antigen protein
11/21/2002	US20020173641 Nucleotide sequences coding polypeptides for use in human therapeutics, pharmacology and diagnostics
11/21/2002	US20020173546 Composition of biochemical compounds involved in bioenergy metabolism of cells and method of use
11/21/2002	US20020173531 Central nervous system disorders; psychological disorders
11/21/2002	US20020173521 Inhibitors of copper-containing amine oxidases
11/21/2002	US20020173507 Antiproliferative agents; apoptosis; anticancer agents
11/21/2002	US20020173505 Antiserotonine agents; respiratory system disorders; antidepressants; eating disorders
11/21/2002	US20020173503 Substituted pyridoindoles as serotonin agonists and antagonists
11/21/2002	US20020173500 Hypotensive agents; antiischemic agents
11/21/2002	US20020173499 Estrogen replacement therapy
11/21/2002	US20020173490 Antidiabetic agents
11/21/2002	US20020173464 Modulation of pericyte proliferation
11/21/2002	US20020173460 Complexing with fibronectins; analyzing, calibration; antiinflammatory agents, respiratory system disorders
11/21/2002	US20020173450 Therapeutic intervention to mimic the effect of caloric restriction
11/21/2002	US20020173449 O-superfamily conotoxin peptides
11/21/2002	CA2460603A1 Unigene unidirectional antisense library
11/21/2002	CA2451116A1 Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
11/21/2002	CA2447593A1 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
11/21/2002	CA2447576A1 Use of hmg fragment as anti-inflammatory agents
11/21/2002	CA2447408A1 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes
11/21/2002	CA2447314A1 Arginine derivatives
11/21/2002	CA2447292A1 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002	CA2447286A1 Random gene unidirectional antisense library
11/21/2002	CA2447015A1 Insulin producing cells derived from human embryonic stem cells
11/21/2002	CA2447004A1 Antisense modulation of ptp1b expression
11/21/2002	CA2446988A1 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	CA2446980A1 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
11/21/2002	CA2446879A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
11/21/2002	CA2446859A1 Transgenic animal model of bone mass modulation
11/21/2002	CA2446821A1 Hbm variants that modulate bone mass and lipid levels
11/21/2002	CA2446797A1 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
11/21/2002	CA2446740A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
11/21/2002	CA2446720A1 High density lipoprotein-reactive peptides

1 ... 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 ... 1298